Physician profile
Robert B Chambliss
NPI 1780611202
$3,652.11
in general payments reported to CMS, 2019-2025
18 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $408 · 2021: $517 · 2022: $178 · 2023: $186 · 2024: $729 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.76 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $672.50 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $512.06 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $442.88 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $316.25 | 2021-2025 | Vraylar |
| Alkermes, INC. | $293.69 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $237.19 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $224.02 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.54 | 2021-2025 | Caplyta |
| Allergan, INC. | $134.96 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $132.71 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $101.52 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $85.98 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $77.38 | 2020-2025 | Trintellix |
| Indivior INC. | $69.97 | 2019-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $69.39 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $52.09 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $43.22 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $19.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chambliss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.